Project: Anti B-Cell 2-specific Antibody for the treatment of chronic Lymphocytic Leukaemia
ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Upon completion of the project, the product will be ready for further clinical development.
Acronym | ABC2ALL (Reference Number: 10506) |
Duration | 15/11/2016 - 15/11/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |